Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1946 3
1951 1
1955 1
1961 1
1969 1
1970 1
1971 1
1972 1
1973 2
1978 3
1982 1
1983 2
1984 1
1985 4
1986 5
1987 6
1988 1
1989 3
1990 3
1991 4
1992 3
1993 2
1994 7
1995 8
1996 13
1997 12
1998 12
1999 10
2000 8
2001 8
2002 5
2003 3
2004 11
2005 9
2006 14
2007 8
2008 6
2009 9
2010 16
2011 15
2012 13
2013 12
2014 17
2015 21
2016 23
2017 34
2018 22
2019 21
2020 21
2021 15
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

382 results
Results by year
Filters applied: . Clear all
Page 1
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ. Li J, et al. Among authors: hay ca. Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26. Immunity. 2018. PMID: 29958801 Free PMC article.
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I, Kazmi R, Chowdary P, Gercheva-Kyuchukova L, Mamonov V, Timofeeva M, Soh CH, Garg P, Vaishnaw A, Akinc A, Sørensen B, Ragni MV. Pasi KJ, et al. Among authors: hay cr. N Engl J Med. 2017 Aug 31;377(9):819-828. doi: 10.1056/NEJMoa1616569. Epub 2017 Jul 10. N Engl J Med. 2017. PMID: 28691885 Free article. Clinical Trial.
Targeting CD73 in the tumor microenvironment with MEDI9447.
Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF. Hay CM, et al. Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug. Oncoimmunology. 2016. PMID: 27622077 Free PMC article.
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage A, Slørdahl TS, Rø TB, Rustad E, Sundan A, Hay C, Cooper Z, Schuller AG, Woessner R, Borodovsky A, Menu E, Børset M, Sponaas AM. Yang R, et al. Among authors: hay c. J Immunother Cancer. 2020 May;8(1):e000610. doi: 10.1136/jitc-2020-000610. J Immunother Cancer. 2020. PMID: 32409420 Free PMC article.
Reply.
Hay CA, Mallen CD, Belcher J, Roddy E, Prior JA. Hay CA, et al. Arthritis Care Res (Hoboken). 2022 Jan;74(1):161-162. doi: 10.1002/acr.24777. Epub 2021 Dec 22. Arthritis Care Res (Hoboken). 2022. PMID: 34477323 No abstract available.
Emicizumab in Hemophilia A.
Kruse-Jarres R, Hay CRM. Kruse-Jarres R, et al. Among authors: hay crm. N Engl J Med. 2020 Feb 20;382(8):785. doi: 10.1056/NEJMc1916299. N Engl J Med. 2020. PMID: 32074440 No abstract available.
Acquired haemophilia.
Hay CR. Hay CR. Baillieres Clin Haematol. 1998 Jun;11(2):287-303. doi: 10.1016/s0950-3536(98)80049-8. Baillieres Clin Haematol. 1998. PMID: 10097808 Review.
382 results